Radiotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Radiotherapy, including details on cancer treatment, side effects.

Volume 7 (2010), Issue 10 (October)

1. Effect of recombinant human keratinocyte growth factor (Δ23rHuKGF, Palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation.
   Int J Radiat Biol, 86(10): 860-6. [Abstract] [Full-text]
2. Definitive radiation therapy for moderately advanced laryngeal cancer: effects of accelerated hyperfractionation.
   Jpn J Clin Oncol, 40(10): 944-8. [Abstract] [Full-text]
3. Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
   Jpn J Clin Oncol, 40(10): 921-6. [Abstract] [Full-text]
4. Stereotactic radiosurgery for deep-seated cavernous malformations: a move toward more active, early intervention. Clinical article.
   J Neurosurg, 113(4): 691-9. [Abstract] [Full-text]
5. Treatment of brain arteriovenous malformations with high-flow arteriovenous fistulas: risk and complications associated with endovascular embolization in multimodality treatment. Clinical article.
   J Neurosurg, 113(4): 715-22. [Abstract] [Full-text]
6. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
   Am J Clin Oncol, 33(5): 481-8. [Abstract] [Full-text]
7. Recurrent nasopharyngeal carcinoma: current management approaches.
   Am J Clin Oncol, 33(5): 469-73. [Abstract] [Full-text]
8. Breast conserving surgery and accelerated partial breast irradiation after prior breast radiation therapy.
   Am J Clin Oncol, 33(5): 427-31. [Abstract] [Full-text]
9. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial.
   Cancer, 116(20): 4677-85. [Abstract] [Full-text]
10. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Cancer, 116(20): 4761-8. [Abstract] [Full-text]
11. Coil spring fiducial markers placed safely using navigation bronchoscopy in inoperable patients allows accurate delivery of CyberKnife stereotactic radiosurgery.
    J Thorac Cardiovasc Surg, 140(5): 1137-42. [Abstract] [Full-text]
12. New antibody conjugates in cancer therapy.
    ScientificWorldJournal, 10: 2070-89. [Abstract] [Full-text]
13. Analytical investigation of the possibility of parameter invariant TCP-based radiation therapy plan ranking.
    Acta Oncol, 49(8): 1324-33. [Abstract] [Full-text]
14. Hypofractionated adjuvant whole breast radiotherapy: progress and prospects.
    Acta Oncol, 49(8): 1288-92. [Abstract] [Full-text]
15. Coil spring fiducial markers placed safely using navigation bronchoscopy in inoperable patients allows accurate delivery of CyberKnife stereotactic radiosurgery.
    J Thorac Cardiovasc Surg, 140(5): 1137-42. [Abstract] [Full-text]
16. From cell population models to tumor control probability: including cell cycle effects.
    Acta Oncol, 49(8): 1315-23. [Abstract] [Full-text]
17. Relative biological effectiveness of photon energies used in brachytherapy and intraoperative radiotherapy techniques for two breast cancer cell lines.
    Acta Oncol, 49(8): 1261-8. [Abstract] [Full-text]
18. Do we need fractionation-corrected doses in sequential two-phase treatments? A quantification of dose differences between non-corrected and corrected combined non-uniform dose distributions in normal tissue.
    Acta Oncol, 49(8): 1253-60. [Abstract] [Full-text]
19. A review of in vitro experimental evidence for the effect of spatial and temporal modulation of radiation dose on response.
    Acta Oncol, 49(8): 1344-53. [Abstract] [Full-text]
20. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia.
    Acta Oncol, 49(8): 1304-14. [Abstract] [Full-text]
21. Clinical heterogeneity and tumor control probability.
    Acta Oncol, 49(8): 1385-7. [Abstract] [Full-text]
22. Dose-painting IMRT optimization using biological parameters.
    Acta Oncol, 49(8): 1374-84. [Abstract] [Full-text]
23. Population TCP estimators in case of heterogeneous irradiation: a new discussion of an old problem.
    Acta Oncol, 49(8): 1293-303. [Abstract] [Full-text]
24. Reproductive outcomes for survivors of childhood cancer.
    Obstet Gynecol, 116(5): 1171-83. [Abstract] [Full-text]
25. Reproductive outcomes for survivors of childhood cancer.
    Obstet Gynecol, 116(5): 1171-83. [Abstract] [Full-text]
26. Practical guidelines for routine intensity-modulated radiotherapy verification: pre-treatment verification with portal dosimetry and treatment verification with in vivo dosimetry.
    Br J Radiol, 83(995): 949-57. [Abstract] [Full-text]
27. Validity of the graded prognostic assessment-derived index to predict brain-metastatic patients' survival after Gamma Knife radiosurgery.
    Int J Radiat Oncol Biol Phys, 78(4): 1156-62. [Abstract] [Full-text]
28. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1104-10. [Abstract] [Full-text]
29. Use of 3.0-T MRI for stereotactic radiosurgery planning for treatment of brain metastases: a single-institution retrospective review.
    Int J Radiat Oncol Biol Phys, 78(4): 1142-6. [Abstract] [Full-text]
30. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.
    Int J Radiat Oncol Biol Phys, 78(4): 1253-60. [Abstract] [Full-text]
31. Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1244-52. [Abstract] [Full-text]
32. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1261-9. [Abstract] [Full-text]
33. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1033-9. [Abstract] [Full-text]
34. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Int J Radiat Oncol Biol Phys, 78(4): 1064-72. [Abstract] [Full-text]
35. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 998-1004. [Abstract] [Full-text]
36. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer.
    Int J Radiat Oncol Biol Phys, 78(4): 1135-41. [Abstract] [Full-text]
37. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
    Int J Radiat Oncol Biol Phys, 78(4): 1005-10. [Abstract] [Full-text]
38. A more efficient, radiation-free alternative to systematic chest x-ray for the detection of embolized seeds to the lung.
    Int J Radiat Oncol Biol Phys, 78(4): 1052-6. [Abstract] [Full-text]
39. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Int J Radiat Oncol Biol Phys, 78(4): 1073-80. [Abstract] [Full-text]
40. Validity of the graded prognostic assessment-derived index to predict brain-metastatic patients' survival after Gamma Knife radiosurgery.
    Int J Radiat Oncol Biol Phys, 78(4): 1156-62. [Abstract] [Full-text]
41. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1104-10. [Abstract] [Full-text]
42. Use of 3.0-T MRI for stereotactic radiosurgery planning for treatment of brain metastases: a single-institution retrospective review.
    Int J Radiat Oncol Biol Phys, 78(4): 1142-6. [Abstract] [Full-text]
43. Bone regeneration after radiotherapy in an animal model.
    J Oral Maxillofac Surg, 68(11): 2802-9. [Abstract] [Full-text]
44. Efficacy of pre- and postirradiation hyperbaric oxygen therapy in the prevention of postextraction osteoradionecrosis: a systematic review.
    J Oral Maxillofac Surg, 68(11): 2653-60. [Abstract] [Full-text]
45. Limited resection followed by intraoperative seed implantation is comparable to stereotactic body radiotherapy for solitary lung cancer.
    Cancer, 116(21): 5047-53. [Abstract] [Full-text]
46. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model.
    Int J Radiat Oncol Biol Phys, 78(4): 1253-60. [Abstract] [Full-text]
47. Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1244-52. [Abstract] [Full-text]
48. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1261-9. [Abstract] [Full-text]
49. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 1033-9. [Abstract] [Full-text]
50. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Int J Radiat Oncol Biol Phys, 78(4): 1064-72. [Abstract] [Full-text]
51. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy.
    Int J Radiat Oncol Biol Phys, 78(4): 998-1004. [Abstract] [Full-text]
52. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer.
    Int J Radiat Oncol Biol Phys, 78(4): 1135-41. [Abstract] [Full-text]
53. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
    Int J Radiat Oncol Biol Phys, 78(4): 1005-10. [Abstract] [Full-text]
54. A more efficient, radiation-free alternative to systematic chest x-ray for the detection of embolized seeds to the lung.
    Int J Radiat Oncol Biol Phys, 78(4): 1052-6. [Abstract] [Full-text]
55. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Int J Radiat Oncol Biol Phys, 78(4): 1073-80. [Abstract] [Full-text]
56. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients.
    Otolaryngol Head Neck Surg, 143(5): 662-8. [Abstract] [Full-text]
57. Growth in children with acute lymphoblastic leukemia during treatment.
    J Pediatr Hematol Oncol, 32(8): e304-7. [Abstract] [Full-text]
58. Growth in children with acute lymphoblastic leukemia during treatment.
    J Pediatr Hematol Oncol, 32(8): e304-7. [Abstract] [Full-text]
59. Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma.
    Pediatr Blood Cancer, 55(6): 1210-2. [Abstract] [Full-text]
60. Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma.
    Pediatr Blood Cancer, 55(6): 1210-2. [Abstract] [Full-text]
61. Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma.
    Pediatr Blood Cancer, 55(6): 1210-2. [Abstract] [Full-text]
62. Management of sialoblastoma with surgery and brachytherapy.
    Pediatr Blood Cancer, 55(7): 1427-30. [Abstract] [Full-text]
63. Management of sialoblastoma with surgery and brachytherapy.
    Pediatr Blood Cancer, 55(7): 1427-30. [Abstract] [Full-text]
64. Management of sialoblastoma with surgery and brachytherapy.
    Pediatr Blood Cancer, 55(7): 1427-30. [Abstract] [Full-text]
65. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.
    J Clin Oncol, 28(31): 4687-96. [Abstract] [Full-text]
66. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.
    J Clin Oncol, 28(31): 4687-96. [Abstract] [Full-text]

© 2004-2012 Radiotherapy Research Today. All Rights Reserved.